Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Instruments & Supplies

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Revenue projections:

Revenue projections for BAX
Revenue projections for BAX

With BAX's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 1.854000
forwardPE 8.601744
debtToEquity 161.021000
earningsGrowth 0.000000
revenueGrowth 0.029000
grossMargins 0.346470
operatingMargins 0.060350
trailingEps -1.910000
forwardEps 2.011220

BAX's current ratio of 1.854 highlights the company's ability to easily cover its short-term debt using its available cash and assets. This indicates a strong liquidity position, ensuring BAX is unlikely to face difficulties in meeting immediate financial obligations.
BAX's high debt-to-equity ratio points to a heavily leveraged company. With more debt than equity, BAX may face increased financial risk, especially if its earnings or cash flow come under pressure.

Price projections:

Price projections for BAX
Price projections for BAX

Baxter International Inc.'s price has frequently been situated near the lower end of analysts' projections. This trend indicates that the stock is struggling to meet expectations, which could signal a need for improvements in performance or investor confidence.

Recommendation changes over time:

Recommendations trend for BAX
Recommendations trend for BAX


The analysts' recent buy bias for BAX indicates strong confidence in the stock's future performance. This could encourage more investors to view BAX as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.